Concomitant cutaneous T‐cell lymphoma and biclonal B‐cell lymphoproliferative disorder

C. Derosa(Ospedale Generale Regionale Francesco Miulli), Pellegrino Musto(University of Bari Aldo Moro), Valentina Tabanelli(Istituti di Ricovero e Cura a Carattere Scientifico), Giuseppe Ingravallo(University of Bari Aldo Moro), Tommasina Perrone, Raffaele Filotico(University of Bari Aldo Moro), Anna Mestice(University of Bari Aldo Moro), Michele Troia(Ospedale Generale Regionale Francesco Miulli)
Cytometry Part B Clinical Cytometry
August 14, 2024
10.1002/cyto.b.22200
Cited by 1

Related Papers

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients
|Blood|2011|268
Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma
|Journal of Clinical Oncology|2010|268
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved Survival
|Journal of Clinical Oncology|2014|210
Accuracy in melanoma detection: A 10-year multicenter survey
|Journal of the American Academy of Dermatology|2011|209